Santhera Pharma gets US, Canadian rights for Fipamezole from Biovail
Fipamezole is being prepared for Phase III development for the treatment of Dyskinesia in Parkinson’s Disease. Previously, Santhera has entered into a collaboration and licensing agreement with Biovail
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.